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Abstract
Objective. Distinguishing between malignant and benign biliary strictures remains problematic. The aim of this study was to
compare and contrast the clinical features of patients with benign and malignant biliary strictures.Methods. Medical records of
patients who underwent surgical resection for presumed cholangiocarcinoma were reviewed. Immunohistochemistry for
hypoxia inducible factor-1-alpha (HIF-1-alpha) was performed on all bile ductule samples. Results. Twelve patients with
benign strictures (group I) were compared to 26 patients with cholangiocarcinoma (group II). Group I was predominantly
female (ratio 2 : 1), (p50.01), whereas the gender ratio was 1 : 1 in patients in group II. Bismuth–Corlette type strictures in
group I were more likely to be type I/II, whereas type III strictures predominated in group II. The CA 19-9 was5100 U/ml in
6 and4100 U/ml in 1 patient of group I and5100 in 13 and4100 in 11 patients in group II. Half of the patients in group I
had positive immunoreactivity for HIF-1-alpha in bile ductules. Conclusion. Benign biliary strictures masquerading as
cholangiocarcinomas occur more often in women, are less often Bismuth–Corlette type III, have serum CA 19-9 values
5100 U/ml, and hypoxia may play a role in a subset of these strictures.
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Introduction
Extrahepatic biliary strictures are often challenging
diagnostic dilemmas. Patients may present with
jaundice, cholangitis, isolated serum alkaline phospha-
tase elevations, or bile duct dilatation on imaging
studies. These symptoms are diagnostically non-
specific. Moreover, imaging modalities may also
be non-specific. Cholangiograms, endoscopic and/or
percutaneous, may display the site and extent of the
stricture, but in the absence of stones, mass, adeno-
pathy or the more diffuse biliary changes of primary
sclerosing cholangitis (PSC), the underlying aetiology
remains unclear. Cross-sectional imaging studies of the
liver and bile ducts—computed tomography (CT) and
magnetic resonance imaging (MRI)—can reveal bile
duct dilation, atrophy of an obstructed lobe and
hypertrophy of a contralateral lobe, masses, regional
lymphadenopathy and loss of lobar blood flow. Masses
and vascular encasement imply neoplastic obstruction.
Lymphadenopathy, however, is non-specific. Unfortu-
nately, tissue diagnosis is difficult given limited access
to the bile duct, and the highly desmoplastic nature of
biliary tract cancers. Negative biopsies and brushings,
therefore, do not exclude bile duct cancers. Even with
advanced cytological techniques such as digital image
analysis and fluorescent in situ hybridization for
aneuploidy, brushings and biopsies are frequently
falsely negative [1].
The differential diagnosis of biliary strictures
includes cholangiocarcinoma, gall bladder cancer,
metastatic cancer to the perihilar region of the liver,
primary and secondary sclerosing cholangitis, granu-
lomatosis disease, biliary tract stone disease, surgical
trauma and so-called “idiopathic strictures”. A major
dilemma is distinguishing idiopathic strictures from
early cholangiocarcinoma. Because current imaging
and diagnostic modalities cannot exclude malignancy,
all biliary strictures are approached from a manage-
ment perspective as if they are malignant. In 8–13% of
most surgical series on cholangiocarcinoma, the bile
duct stricture is inflammatory and benign [2,3].
Accurate diagnosis of these idiopathic, inflammatory
strictures may permit conservative stenting approaches
without surgical extirpation. More information is
necessary to characterize these strictures for accurate
preoperative diagnosis.
The aetiopathogenesis of these idiopathic biliary
strictures remains enigmatic. The biliary tree is quite
susceptible to ischaemic injury. The tissue response to
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chronic ischaemia is to adapt by expressing survival
proteins. One adaptation to ischaemia is the expression
of hypoxia inducible factor (HIF-1-alpha) [4]. Expres-
sion of this transcription factor can be identified by
immunohistochemistry [4,5] and therefore, its expres-
sion may provide insight into the pathogenesis of
idiopathic strictures.
Thus, the overall objective of this study was to
further characterize idiopathic biliary strictures
through a review of our clinical experience. These
findings were compared to a group of patients who
underwent surgical resection for proven cholangiocar-
cinoma. Our data suggest that idiopathic strictures
occur more often in women and are more likely to
include the mid-duct region than cholangiocarcino-
mas. A subset of these strictures may be ischaemic
based on ductule expression of HIF-1-alpha.
Methods
Patient groups
This minimal risk retrospective study was approved by
the Mayo Institution Review Board. We reviewed the
medical records of patients who underwent surgical
resections or exploration for presumed cholangiocarci-
noma between 1990 and 2003. Clinical features,
laboratory results, cholangiogram, imaging studies,
surgical reports and histopathology were reviewed
in the 12 patients with idiopathic benign strictures
(group I) and compared with 26 patients with
cholangiocarcinoma (group II) diagnosed over the
same period. Patients with a diagnosis of PSC,
inflammatory bowel disease, choledocholithiasis and
previous cholecystectomy and gall bladder carcinoma
were excluded from the study. Diagnosis of idiopathic
benign stricture was confirmed after review by a
hepatopathologist. The diagnosis of cholangiocarci-
noma was also confirmed after histopathology review.
Review of cholangiograms and classification
of biliary strictures
The cholangiograms were reviewed with particular
regard to the site of stricture and biliary dilatation.
The strictures were classified using the anatomical
classification developed by Bismuth and Corlette [6].
Imaging modalities and surgical findings were reviewed
to assess vascular involvement and the atrophy-
hypertrophy complex.
Review of histopathology
The histopathology was reviewed systematically by a
hepatobiliary pathologist. The specimens diagnosed as
cholangiocarcinoma were graded into types I–IV
according to UICC criteria [7]. All tissue underwent
staining for acid-fast bacteria and fungi.
Immunohistochemistry for HIF-1-alpha
Unstained slides of tissue specimens from group I were
deparaffinized and hydrated. Antigen retrieval was
performed using EDTA (1 mM, pH 8.0); slides were
placed in a vegetable steamer for 40 minutes at 97C
followed by a cooling off period of 20 minutes.
Thereafter, the catalysed signal amplification system
(DAKO, Carpinteria, CA, USA) was used for HIF-1-
alpha staining according to the manufacturer’s instruc-
tions [5]. The primary antibody utilized was anti-HIF-
1-alpha mouse monoclonal antibody at a dilution
of 1 : 1000 (Novus Biologicals, Littleton, CO, USA).
Positive specimens required immunoreactivity of bile
duct epithelial cells in 450% of ducts, staining above
background and immunoreactive product in nuclei
consistent with the biology of the transcription factor.
Specimens with indeterminant immunostaining were
considered negative.
Statistics
The results were expressed as mean values+SE.
Statistical significance in mean values was evaluated
by the Student’s t test.
Results
Clinical characteristics
All patients presented with jaundice and proximal bile
duct dilatation on ultrasound and CT imaging studies.
There were 4 men and 8 women in group I compared
with 14 men and 12 women in group II; the gender
prevalence for women in group I was significant
(p50.01). The mean age of patients, serum bilirubin,
AST, ALT and alkaline phosphotase levels in group I
and group II were similar and not statistically different
(Table I). The serum CA 19-9 value was 4100 U/ml
in 11 patients in group II, whereas it was elevated
4100 U/ml in only 1 patient in group I. The patient in
group I with elevated CA 19-9 (2888 U/ml) had active
bacterial cholangitis, a known cause of elevated serum
CA 19-9 values [3].
Diagnostic imaging was not standardized in the
study because of the long duration of the study period.
Ten patients in group I underwent CT; no masses were
identified. Three patients in group I and nine patients
in group II underwent endoscopic ultrasound; two of
three in group I had ultrasonographic evidence for a
mass and eight of nine in group II demonstrated a mass
lesion, p=0.08.
Cholangiography findings
Bismuth–Corlette type strictures were as follows.
Group I: I=6, II=2, IIIa=1, IIIb=2 (Figure 1);
group II: I=5, II=6, III=1, IIIa=4, IIIb=10.
Although group I had Bismuth type IIIa or IIIb
strictures, no vascular encasement or lobar atrophy
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and obstruction of secondary biliary radicals was
observed in this group, but was observed in five
patients in group II.
Surgical intervention
Eight of 12 patients in group I underwent resection of
extrahepatic duct and Roux-en-Y hepaticojejuno-
stomy. One patient underwent pylorus-preserving
Whipple resection for a lesion of the distal bile duct
involving the head of the pancreas. One patient under-
went left hepatectomy and Roux-en-Y hepaticojeju-
nostomy for a stricture of the left hepatic duct
extending to the common hepatic duct with left lobar
firmness. Two patients in group I had a mass noted at
exploration. One patient had a 2-cm mass involving the
common hepatic duct, cystic duct, Calot’s triangle and
distal gall bladder that was subsequently diagnosed
as sarcoidosis. The second patient had a 2-cm firm
thick mass at the level of common hepatic duct and
common bile duct whilst in remission from chronic
lymphocytic leukaemia (CLL). This mass was fibrosed
scar tissue, perhaps resulting from chemotherapy-
induced necrosis of his CLL in this region. Both
patients underwent resection of extrahepatic duct and
Roux-en-Y hepaticojejunostomy. Two patients did
not undergo resection, one underwent transduodenal
sphincteroplasty and the other underwent t-tube
Figure 1. Cholangiogram of a benign inflammatory bile duct stricture masquerading as cholangiocarcinoma. This representative
cholangiogram epitomizes the difficulty in distinguishing between malignant and benign biliary strictures via ERC. There is lack of
visualization of the right hepatic ductular system with left ductular dilatation.
Table I. Clinical characteristics of patients
Parameter
Group I: benign
stricture (n=12)
Group II:
cholangiocarcinoma (n=26)
Age (years) (median/range) 59.4 (20.8–79.8) 61.4 (41.8–78.9)
Age (mean) 54.7+15.4 61.4+10.3
Gender (M : F) 4 : 8 14 : 12
Bismuth–Corlette type (I : II : III) 6 : 2 : 4 5 : 6 : 15
Total bilirubin mg/dl (median/range) 4.5 (0.3–21.6) 8.0 (0.4–37.9)
Mean 6.1 10.4
AST/ALT U/l (median) 60.5/83.5 70.5/82.5
Alkaline phosphatase U/l (median) 642.5 (91–2675) 809.5 (290–1722)
CA 19–9 U/ml (5100 :4100) 6 : 1 13 : 11
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choledochostomy; at the time of surgery, malignancy
could not be confirmed and the stricture was assessed
as inflammatory.
Twelve of 26 patients from group II underwent
either left or right hepatectomy, extrahepatic bile duct
resection and hepaticojejunostomy. Seven underwent
extrahepatic bile duct resection and hepaticojejuno-
stomy alone. Three patients had a Whipple resection
for localized distal bile duct disease, two of which
were pylorus-preserving procedures. Four patients had
unresectable disease noted by laparotomy or laparo-
scopy, secondary to peritoneal carcinomatosis and
portal vein invasion.
Clinical outcomes
Two patients in group I have died. Both patients
underwent extrahepatic duct resection and Roux-en-Y
hepaticojejunostomy. One patient died 8 years after
resection from biliary cirrhosis and the other from
transitional cell carcinoma of the bladder 3 years after
biliary resection. The patient who developed biliary
cirrhosis also had recurrent intrahepatic biliary
strictures and hepaticolithiasis. The aetiology of this
progressive stricturing syndrome was unclear. Eight
patients remain healthy without recurrent disease
4–9 years after biliary resection. The patient who
underwent t-tube choledochostomy experienced
progressive intrahepatic stricturing from presumed
PSC, and one patient was lost to follow-up. In contrast,
none of the patients with cholangiocarcinoma,
group II patients, had long-term survival (no 5-year
survivors).
Immunohistochemistry for HIF-1- alpha in
patients with benign strictures
HIF-1-alpha immunoreactivity was positive in 50%
(6/12) of the patients in the benign biliary stricture
group (Figure 2). Thus, a subset of these patients had
biochemical and histological evidence for ongoing
ischaemia or hypoxia within the resected biliary speci-
men. There was minimal to no immunoreactivity in
the patient with sarcoidosis or the patient in remission
from CLL as expected. As anticipated in an avascular
cancer such as cholangiocarcinoma, all biliary tissue
specimens from group II were positive for HIF-1-alpha
immunoreactivity (data not shown).
Figure 2. Hypoxia inducible factor-1-alpha (HIF-1-alpha) is present in benign inflammatory bile duct strictures. Representative
photomicrographs of biliary duct tissue specimens after immunohistochemical staining of HIF-1-alpha. (A) Positive staining of HIF-1-
alpha in ductular epithelium (magnificationr20). (B) A higher magnification of (A) illustrating definite nuclear staining (arrows) (r40). (C)
A biliary tissue specimen negative for HIF-1-alpha; note the lack of nuclear staining in ductular epithelium and clear nuclei.
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Discussion
We examined a select group of patients with idiopathic
biliary strictures by excluding patients with focal
strictures secondary to primary sclerosing cholangitis
(PSC), associated inflammatory bowel disease and
choledocholithiasis. Our study demonstrates that
patients with idiopathic biliary strictures are more
likely to be women, demonstrate normal CA 19-9
levels, less frequently have strictures involving the bile
duct confluence, and a subset of these strictures
expressed HIF-1-alpha which is consistent with tissue
hypoxia.
This study demonstrates that patients with benign
strictures are more likely to have strictures of Bismuth–
Corlette type I and II; in contrast patients with
cholangiocarcinoma are more likely to have types II,
III, IV. Our findings differ from those of the study by
Verbeek et al. [8], who described predominantly type
III strictures in more than half their 11 patients.
However, our data are similar to those of Hadjis et al.
[2], as all their patients exhibited type I or II strictures.
Therefore, we suggest that strictures below the biliary
confluence are more likely to be benign. However,
most de novo strictures are malignant.
The location of these strictures is analogous to those
occurring following cholecystectomy, which may be
type III [9] or more than half the time type I–II because
of compromise of axial and tenuous blood supply of the
supraduodenal segment of the bile duct. [10]. These
observations lead us to speculate that vascular com-
promise may contribute aetiologically to idiopathic
benign biliary strictures. To examine the hypothesis
that vascular compromise and hypoxia may play a role
in benign biliary strictures we performed immunohis-
tochemical staining for HIF-1-alpha on excised biliary
tissue from the benign stricture group. HIF-1-alpha is a
transcription factor that is expressed in response to a
decrease in the partial pressure of cellular oxygen and
activates genes involved in glycolysis, modulation of
vascular tone, angiogenesis and erythropoiesis [4,11].
We found that approximately half were positive for
HIF-1-alpha protein in the nucleus. These data
support hypoxic injury as a potential cause for benign
biliary strictures. However, it is also possible that
stricture formation itself may have rendered the tissue
hypoxic. Nonetheless, hypoxia even as a secondary
rather than an inciting event would likely contribute to
stricture progression.
Two of six tissue specimens negative for HIF-1-
alpha immunostaining had probable causes other than
hypoxia. One stricture was most likely secondary to
sarcoidosis. Although rare, cholestasis in sarcoidosis
may be attributable to extrahepatic biliary ductal
obstruction from sarcoid [12,13] or enlarged lymph
nodes of the portahepatis [14]. The second patient
likely had a stricture arising from chemotherapy for
CLL. Rarely injury to the bile duct following radiation
[15] and chemotherapy for lymphoma [16] has
resulted in biliary stricture. Such a complication may
have contributed to the stricture in this patient,
although he was in remission from CLL. Recognizing
these clinical scenarios as potential causes of benign
strictures may help in their management.
Despite improvements in imaging techniques during
the last decade, radically distinguishing benign from
malignant strictures still remains a challenge [17,18].
ERC or MRC is helpful in identifying the site and
extent of stricture but not the aetiology [19,20].
Endoscopic biopsies and brushings are only positive
in 15–70% of patients with cholangiocarcinoma [21].
The difficulty of applying imaging techniques to clearly
differentiate benign from a malignant process is high-
lighted by a non-contributory result from endoscopic
ultrasound (EUS) in 3 of the 12 patients in the benign
idiopathic group who underwent the procedure, 2 of
whom had imaging criteria for a mass lesion. The
presence of lymphadenopathy does not differentiate
between malignancy and benign stricture; in fact,
lymphadenopathy may be reactive and occur either as
a part of the primary process or following placement of
stents [1,22]. The results from newer techniques such
as digitalized image analysis and fluorescent in situ
hybridization [21,23] appear to be promising but need
validation.
In conclusion, benign biliary strictures masquerad-
ing as cholangiocarcinomas occur more often in
women and are less often Bismuth–Corlette type III
than true malignant lesions. In the absence of
cholangitis, serum CA 19-9 values are also seldom
4100 U/ml in benign strictures. A subset of patients
appears to have a hypoxic component, which may
lead to the development of their benign biliary
strictures.
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